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Abstract 
  
 
Introduction: Opioid addiction and abuse continues to reach epidemic status in the United 
States. Many individuals who desire treatment are unable to do so. Buprenorphine is one 
method of Medication Assisted Treatment (MAT) that can be prescribed by any outpatient 
physician who completes training and obtains a waiver - however, provider uptake of 
buprenorphine has been low. This paper sought to examine the barriers to provider uptake of 
buprenorphine, as well as analyze relevant policy to help inform future solutions 
 
Methods: A limited systematic review examining provider attitudes and beliefs surrounding 
buprenorphine, followed by a policy analysis with recommendations for future policy.  
 
Results: Search strategy yielded 201 articles, 64 articles screened after duplicate removal, 19 
articles assessed for eligibility and 9 articles identified for full review. Key barriers identified 
included stigma towards addiction population, lack of support & resources, as well as lack of 
training. The role of Medicaid, the Affordable Care Act, and other legislation and policies in 
substance abuse treatment and buprenorphine adoption was discussed.  
 
Conclusion: Despite growth in the number of waivered physicians, crucial barriers towards 
physician adoption of buprenorphine remain. Training early in a clinician’s career, increased 
financial remuneration for addiction treatment, and other programs to facilitate provider support 
might be essential towards changing the culture and attitudes of providers towards the addiction 
population and promoting buprenorphine use. 
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 Introduction 
 
Opioid abuse and addiction are major public health problems in the United States. Now 
classified as an epidemic (CDC Injury Center, 2017), the current wave of addiction has been 
fueled largely by prescription drug use succeeded by a subsequent spike in heroin abuse. In 
2015, drug overdose was the leading cause of accidental death in the US, with more than half of 
these deaths related to prescription pain and heroin overdoses - comprising around 32,000 
deaths in 2015 (ASAM, 2016). It is estimated that 2.5 million adults and adolescents have a 
substance abuse disorder involving prescription pain relievers and/or heroin (ASAM, 2017). The 
cost of this epidemic has been estimated to be $55 billion annually (Birnbaum et al., 2011) and 
has been associated with increased rates of crime, HIV acquisition, and hepatitis C infection, 
among other negative outcomes (Schukit, 2016). The epidemic has steadily worsened 
throughout the past few decades: from 2000 to 2015, overdose deaths from opioids have 
increased 2.8 fold (National Institute on Drug Abuse, 2017). The epidemic has placed a 
tremendous burden on families and communities – for example, there has been a national surge 
in the number of children in the foster care system that is thought to be directly related to the 
opioid epidemic (Wiltz, 2016). Rural areas have been especially affected, with higher rates of 
overdose as compared to urban areas (Keyes et al, 2014). These facts and statistics 
demonstrate the need for broad access to effective solutions and treatment modalities.  
 
This paper will investigate medication-assisted treatment (MAT) for opioid abuse, focusing on 
buprenorphine, one agent in the category of MAT agents. MAT is a general strategy of 
treatment that combines pharmacotherapy with mental health and social support to help treat 
opioid addiction. Buprenorphine is part of a treatment paradigm originally intended to create 
broad access to substance abuse treatment by allowing office-based treatment by any 
physician, provided they complete training and obtain a federal waiver. However, despite the 
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aim of widespread adoption, provider uptake of buprenorphine has been low. Thus, the main 
research question of this paper is how to expand provider use of buprenorphine. I investigate 
this question by synthesizing a limited systematic review of the literature providing evidence of 
barriers to providers with a review of current policies related to MAT.  I conclude with evidence 
based recommendations for future policy solutions.  
 
Medication Assisted Treatment for Opioid Abuse 
As stated above, MAT is one method of treatment of opioid abuse. The general purpose of MAT 
is to provide pharmacotherapy to opioid dependent patients to reduce cravings and withdrawal 
symptoms, while minimizing euphoric effects. Ideally, this allows the patient to avoid drug 
abuse, avoid negative behaviors and activities associated with addiction, remain in treatment, 
and maintain productive lives.  Many patients can be weaned off of MAT in time; while others 
take it indefinitely (SAMHSA, 2015). It is not usually meant to be used as a singular, exclusive 
treatment modality, but rather one component of comprehensive, multi-pronged treatment that 
often includes some form of mental health therapy as well (SAMHSA, 2015). The benefits of 
MAT therapy are proven (Schuckit, 2016; Volkow, 2014), and include lower overdose rates, 
higher rates of retention in treatment, improved social functioning, reduced transmission rates of 
infectious diseases such as HIV and hepatitis C, and reduced rates of engagement in criminal 
activity (Volkow, 2014).  
 
Historically, methadone was the primary method of MAT. Methadone is a full opioid agonist 
(e.g., a drug that fully engages the opioid receptors in the brain) that is usually administered 
orally and taken once a day. However, by law, methadone administration is limited to heavily 
regulated treatment centers, which restricts its accessibility to patients and thus its use. 
Buprenorphine (brand names Subutex, or Suboxone when the buprenorphine is combined with 
naloxone) is a partial opioid agonist (e.g.. it binds and activates opioid receptors but less 
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completely than is true of full agonists), approved by the Food and Drug Administration (FDA) in 
2003 for office-based treatment for opiate use disorders (Li et al., 2014). Since it can be 
prescribed in an average ambulatory setting, via the Drug Addiction Treatment Act of 2000, it is 
not limited to certain treatment centers, as is methadone. The putative ease of prescribing 
buprenorphine theoretically widely expands access to treatment. Buprenorphine is thought to 
have a better safety profile than does methadone, including lesser risk of overdose, as well as 
lower risk of abuse (Li et al, 2014). Buprenorphine has been demonstrated to be effective in 
maintenance treatment of opioid dependence and suppression of illicit opioid use, and is 
comparable in effectiveness at fixed medium and high doses to methadone (Mattick et al, 2014). 
Effectiveness in studies of buprenorphine in retaining patients in treatment has been 
demonstrated to be in the 40% range – similar to that of methadone (Fiellin et al, 2008; Fiellin et 
al, 2006; Parran et al, 2012). Unlike methadone use, which usually mandates daily observed 
intake at these treatment centers and reserving take-home medications only for patients that 
have demonstrated compliance over time, buprenorphine can be taken at home.  
Buprenorphine prescriptions also come without the perceived stigma amongst potential patients 
of methadone clinics - thought to result from the common location of these clinics in low-income 
urban areas (Gryczynski et al, 2014). Patients also might prefer a choice of buprenorphine over 
methadone because it makes it easier to maintain a job or perform other commitments, since 
one does not have to attend a clinic every day for administration (Gryczynski et al, 2014). The 
outpatient-based nature of treatment makes it an appealing option to help counter the growing 
opioid crisis - there continues to be a substantial gap between those who seek treatment for 
opioid dependence, and those who are actually able to access treatment (SAMHSA, 2015). 
Speaking more broadly about substance abuse, it has been estimated that only 10.9% of those 
that need treatment actually receive it (SAMSHA, 2014).  
 
 4 
 
Providers are able to prescribe buprenorphine for MAT by applying for a waiver through the 
Drug Enforcement Agency (DEA), after completing 8 hours of required training (SAMHSA, 
2017). This waiver allows physicians to treat up to 30 patients in their first year, after which they 
can expand their panel of buprenorphine patients to a maximum of 100, with a recently 
expanded maximum cap of 275 patients after a certain period of time (SAMHSA, 2016). 
Physician Assistants (PAs) and Nurse Practitioners (NPs) were also given the ability to 
prescribe buprenorphine for opioid dependency treatment by the Comprehensive Addiction and 
Recovery Act of 2016, although their ability to prescribe varies from state to state (discussed in 
greater detail later in this paper). Currently, around 25,000 physicians nationwide are certified to 
prescribe buprenorphine under the waiver process (SAMHSA, 2016). However, it is estimated 
that 40% of waivered physicians don’t prescribe the drug at all (Moran, 2016; SAMHSA, 2016). 
The number of providers signed up to prescribe buprenorphine has increased steadily over the 
years (Arfken et al, 2010), but despite this increase, the number of providers authorized to 
prescribe buprenorphine has not caught up with the demand created by the continued opioid 
crisis. In fact, it has been estimated that only 3% of primary care physicians and 16% of all 
psychiatrists have signed up to receive a waiver (Rosenblatt et al, 2015). Additionally, most of 
these physicians are located in urban areas, and not in the rural areas where the opioid 
epidemic has been particularly damaging (Rosenblatt et al, 2015).  A report found that despite 
growth in the number of physicians providing buprenorphine, 47% of US counties still had a 
shortage of waivered physicians in 2011 , found in concert with a stable number of methadone 
OTPs nationwide (Dick et al, 2016). In 2012, a study demonstrated that, in a best-case scenario 
in which all waivered physicians were prescribing at their maximum patient limit there was still a 
treatment gap of nearly 1 million people between those that abuse opioids and the treatment 
capacity of buprenorphine providers. This same study found that the majority of states had a 
treatment gap of at least 3 patients per 1000 people (Jones et al, 2015). These findings 
demonstrate a continued shortage of buprenorphine waivered physicians and a persistent 
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treatment gap.  And as only 3% of primary care physicians are signed up to prescribe 
buprenorphine, there is considerable potential for community physicians to help fill this 
treatment gap. Outpatient-based physicians, especially primary care physicians, might also be 
uniquely equipped to become waivered and help combat the epidemic considering that primary 
care physicians can help provide needed longitudinal care and treatment of medical conditions 
associated with opioid addiction, and serve as a gatekeeper to other needed services such as 
mental health therapy and specialty services.  
 
Thus, despite the initial promise and potential for widespread availability, provider adoption of 
buprenorphine for MAT has been disappointing. Identifying barriers from the provider 
perspective is crucial to developing potential solutions and informing policy development, such 
that access to buprenorphine can increase as needed to combat the opioid epidemic. This 
author is not aware of any current systematic review that has examined the reasons behind the 
slow uptake of buprenorphine for MAT. Previous systematic reviews have addressed outpatient 
therapy acceptance largely revolving around methadone (Becker and Fiellin, 2005), but I 
identified none specifically focused on buprenorphine therapy, and the Becker and Fiellin review 
examined articles largely completed before the advent of buprenorphine for MAT, reflecting its 
status as a relatively newer medication for this indication. There is a need for a review that 
examines more current attitudes and barriers, revolving specifically around buprenorphine for 
MAT, and particularly focusing on providers’ willingness to prescribe the treatment. This paper 
uses a limited systematic review of existing literature to identify the reasons behind provider lack 
of uptake of waiver acquisition and buprenorphine prescribing. I also identify facilitators of 
buprenorphine administration. I use findings from this review will to discuss existing policy 
governing buprenorphine and MAT at large, and to inform steps toward an ideal policy to help 
promote the use of buprenorphine for treatment of opioid abuse.  
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Methods 
 
The purpose of the review is to determine and describe, from the literature, barriers to physician 
adoption of buprenorphine for MAT for opioid abuse, followed by an inquiry into relevant policy 
and a discussion of policy steps moving forward. A systematic review of the literature 
concerning provider attitudes, beliefs and barriers to prescribing buprenorphine comprises part 
one of this paper. As this literature is mostly drawn from interview-based studies and small-
sample, questionnaire-based studies, I appraise the literature by departing from the strategy 
more traditionally associated with clinical trials. Many appraisal techniques used to evaluate 
clinical trials such as cohort studies and randomized controlled trials are difficult to apply to 
studies using other research designs. I thus chose to use the Critical Appraisal Skills 
Programme (CAPS) framework for qualitative studies to evaluate the literature I have identified. 
This is a 10-point checklist framework that has been used in published studies to evaluate 
qualitative studies. I evaluated survey-based studies using an adapted framework from the 
aforementioned CAPS checklist, the NIH quality assessment tool for cross-sectional and cohort 
studies, as well as a framework from Saab et al. (2016) developed to help assess survey 
studies After applying these frameworks, I aggregate and discuss common themes observed in 
the reviewed articles. 
 
This review includes published studies that address provider attitudes, beliefs and barriers to 
prescribing buprenorphine for opioid abuse. This review includes both quantitative and 
qualitative studies. I performed a search of 4 major databases (MEDLINE, Psychinfo, Cochrane 
and CINAHL) using the search terms {((opioid) AND buprenorphine) AND (Attitude of Health Personnel OR 
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(physicians AND (attitudes or beliefs))) }, as derived after working with UNC librarian services, with the 
last search occurring on 5/11/2017. 
 
These are the elligibility criteria for reviewed articles: 
- Conducted in the United States, and written in English; 
- Since DATA approval in 2000; 
- Primarily addressing the use buprenorphine for office-based treatment of opioid abuse 
(e.g. not primarily addressing diversion of buprenorphine, factors making patients more 
likely to receive buprenorphine, or other associated topics. Articles discussing both 
buprenorphine and methadone were included, as part of a discussion on overall office 
based treatment, as long as buprenorphine was discussed in a significant manner). 
Office based treatment could be from the perspective of primary care providers, 
psychiatrists, addiction medicine specialists, or other fields which might prescribe 
buprenorphine in an office setting.  
- Articles primarily concerning attitudes and barriers for providers.  
I reviewed titles and abstracts, and excluded those that failed to meet the inclusion criteria listed 
above. For this portion of the study, I also excluded articles if they primarily discussed system-
level barriers, or primarily had institutions, rather than individual prescribers, as the unit of study. 
I was the only reviewer of the remaining articles.  After reviewing the literature, I organized 
findings into common themes (see the “Results” section below).  
 
Results of the limited systematic review  
Including duplicates, I identified a total of 201 articles using the search strategy, and screened 
64 articles after removal of duplicates. From this list, I assessed a total of 19 articles for 
eligibility, and identified a total of 9 articles for review (See figure 1 in the Appendix for a 
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schematic of the search results). The articles were a mix of qualitative and quantitative studies, 
relying on results from both interviews and questionnaires. Articles were also varied in the 
sectors and provider field/specialty that they analyzed: some focused exclusively on primary 
care providers and family medicine doctors, while others examined addiction medicine 
specialists and general psychiatrists. The studies included in this review can be seen in table 
[number]. The literature contains common themes, which I will describe below.  
 
Barriers 
Stigma 
Seven of the nine reviewed studies identified discomfort and unease with the patient population 
as barriers to buprenorphine use. These barriers were described in many ways. One form of 
stigma was demonstrated by the opinions providers had toward opioid-dependent patients. 
These patients were generally perceived as a difficult or undesirable population to work with. As 
an example, a study by Gordon, Kavanagh, Krumm et al (2011) examining perspectives about 
buprenorphine prescribing within the Veterans Health Administration found that “it was clear that 
many physicians .”…do not want these ‘types’ of patients’” on their patient panel or in their 
clinics, (p.218) which represented a common barrier to buprenorphine MAT amongst 
respondents. McMurphy et al., in a study examining attitudes amongst primary care clinic 
directors in New York, found that stigma about opioid-dependent patients was the most 
commonly cited barrier to treatment in their panel, with one director stating that “it’s one of the 
toughest populations for me to deal with in all the areas that I work…most of them haven’t 
changed the behaviors of their addiction, and so you’re constantly chasing them and trying to 
monitor urine drug screens.” (p.546). Clinic directors also used the terms “difficult, manipulative, 
arguing, ...undesirable…,too many social problems” (p.546) to describe their views on patients 
receiving MAT(p546) (McMurphy, Shea, Switzer et al, 2006).  DeFlavio, Rolin, Nordstrom et al. 
identified difficulty treating patients with addiction as a crucial barrier as well, stating that 
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patients with drug addiction “were referred to as ‘high-maintenance,’ ‘stressful,’ and 
‘challenging,’” (p.6) and cited mistrust and negative attitudes towards addicted patients as a 
significant barrier to buprenorphine use. In that same report, the authors found that many 
respondents held the belief that “family physicians would prefer it if patients went elsewhere for 
addiction services.” (p6). Molfenter, Sherbeck, Zehner et al in a study of providers and payors in 
Ohio noted that physicians did not want to initiate buprenorphine prescribing due to fears of 
working with addiction patients, with a board member stating “Doctors do not want to deal with 
this population.” (p.5).  
 
A related barrier was the fear of mixing patient populations, e,g,, patients with opioid abuse 
sharing clinic space with “regular” patients; and the fears that this patient mixing would have on 
the perception of their clinic.  McMurphy et al identified this as a significant barrier, reporting that 
many respondents were concerned about exposing patients such as “pregnant women and 
children” and a “senior population” to “disturbing patients,” and others reporting fear that their 
clinic would be “stigmatized” amongst the community at large where the clinic is located (p.546-
7). Suzuki, Connery, Ellison et al., in a study featuring an online survey of 93 psychiatrists 
comparing attitudes between those that had completed buprenorphine certification and those 
that had not, found that “not [wanting] to attract patients with opioid addiction to my office” 
(p.621) was among the most frequently reported barriers in both those that had and had not 
received training, and was significantly higher among those that did not receive training in 
residency.  In another study analyzing beliefs of psychiatrists and addiction specialists, Thomas, 
Reif, Haq et al found that “[offering buprenorphine] would change the patient mix undesirably” 
(p.913) was amongst the top three most important barriers for respondents. It is clear that a 
reluctance to work with the opioid-dependent population emerges from the stigmatization of this 
population, and stigma is a key barrier to adoption of buprenorphine.  
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Lack of support & resources 
Another prominent theme in the literature was the lack of resources or associated services to 
provide buprenorphine to patients – 7 of the 9 reviewed studies mentioned this barrier. The 
complaint of lack of services included the need for psychological therapy and other behavioral 
health services for patients who abuse opioids. An associated complaint was the lack of time to 
treat these patients and address any needs beyond buprenorphine administration. 
 
McMurphy, Shea, Switzer et al found that many clinic directors identified need for broader 
services, increased volume of patient visits, and challenges for staff, as major barriers to 
prescribing buprenorphine in their clinics. Additionally, 44% of respondents felt that “these 
patients’ psychological needs could not be managed in the clinic,” which reinforced the need for 
increased services to implement outpatient opioid treatment. Hutchinson, Caitlin, Andrilla et al. 
found that lack of mental health care and psychosocial support was the most frequently reported 
barrier to prescribing buprenorphine in their respondent panel of Washington state physicians - 
a variable that was likely exacerbated by a state rule that Medicaid pays for buprenorphine only 
if patients receive concurrent counseling services. DeFlavio et al. found that many family 
physicians stated that they would need easier access to pain management and psychiatric 
services before considering buprenorphine adoption. Time constraints and lack of specialty 
backup were the number two and three most frequently reported barriers in their study, factors 
associated with lack of resources. Lack of resources was also a commonly mentioned barrier in 
the Gordon, Kavanagh, Krumm et al study of VHA implementation, as well as in an article by 
Cunningham, Sohler, McCoy et al. examining provider beliefs in an urban treatment setting – 
there, providers said  they would like available consultation/case-conferences, as well as on-site 
counselors/social workers.  
 
Lack of training 
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Need for training and physician unawareness of buprenorphine as a potential treatment 
modality was another prominent theme in the literature, identified in 6 of the reviewed studies. 
Unawareness of buprenorphine was observed – for example, McMurphy et al. found that less 
than half of their respondents knew about buprenorphine, in contrast to all of them knowing 
about methadone for MAT. Other studies noted lack of training or experience with 
buprenorphine, despite being aware of it as a potential modality, as a significant barrier. 
Cunningham et al. noted that the most frequently stated reason for not prescribing 
buprenorphine among their panel of attending physicians and residents in an urban teaching 
hospital was the lack of knowledge of training.  Lack of training among non-physician staff was 
also recognized as a barrier. ).  DeFlavio, Rolin, Nordstrom et al. found that 88% of their non-
prescribing respondents said inadequately trained staff was a significant barrier. Suzuki, 
Connery, Ellison et al., found that psychiatrists that had completed any training about 
buprenorphine during residency were significantly more likely to have favorable views of 
buprenorphine, as well as reporting significantly fewer barriers to prescribing buprenorphine, 
than was true of residents who had no training during residency. Molfenter, Sherbeck, Zehner et 
al. also noted that physicians not being knowledgeable about buprenorphine was a significant 
barrier to acceptance of the medication.  
 
Other barriers 
Costs. Costs to patients and providers was a theme in many articles. Many articles noted 
that there is no financial incentive to add buprenorphine to one’s practice, given the higher costs 
of needed ancillary services and possibly longer consultation times. Other articles cited the high 
costs of buprenorphine to the patient as a barrier to treatment.  
Regulations.  This barrier was more common in articles that analyzed the attitudes pf 
psychiatrists and addiction specialists, subspecialties with higher rates of waivered providers 
than is true of primary care physicians. Specifically, the patient caps imposed by DATA were 
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identified as a barrier to treatment, with waivered physicians who prescribed buprenorphine 
quickly reaching their caps and becoming unavailable to meet the demand of potentially 
interested patients. Fear of DEA audits was also mentioned as a challenge by providers who 
prescribe buprenorphine in a study by Kissin et al.  
Not a primary care problem.  The view that treatment of opioid abuse falls outside the 
purview of primary care was a theme in this literature. A related finding was the belief that 
treatment of opioid abuse should be limited to psychiatry/ addiction medicine only.  
Disagreement with use of buprenorphine for treatment of opioid addiction/abuse.   
Negative attitudes toward the general philosophy behind MAT appeared in the literature as 
another barrier to buprenorphine use. Providers holding these attitudes often instead favored 
abstinence-based therapies. Molfenter et al noted that staff orientation towards abstinence 
based therapy was a prominent source of resistance to uptake of buprenorphine and general 
medication therapy, exemplified by the quote that “...medication-assisted treatment is 
substituting one drug for another.” (p.5) The resistance of other groups involved in drug abuse 
treatment, such as Narcotics Anonymous, was also noted as a barrier to treatment.  
Fears of diversion.  Concerns about patient diversion of buprenorphine was also noted 
in some studies as a barrier to treatment. Articles noted concerns about the “street value” of 
buprenorphine, as well as fears that significant amounts of buprenorphine would end up in the 
community. Tying back to the theme of stigma, it was feared that the provider’s clinic would be 
known as the source of buprenorphine in the community.  
Facilitators 
I selected the articles I have identified here because they discussed barriers to buprenorphine 
treatment.  Many, however, also discussed facilitators to buprenorphine for MAT. These 
facilitators give useful insight into the context surrounding provider adoption of buprenorphine. 
 
Funding 
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Increased funding for buprenorphine, or financial incentives to prescribe buprenorphine, was 
mentioned as a facilitator in this review. Respondents in McMurphy et al noted that an 
enhanced Medicaid clinic rate would help incentivize providers to prescribe buprenorphine, as 
well as assist in funding associated services such as social work. Special remuneration for 
buprenorphine was also a highly discussed facilitator in the study by DeFlavio et al of family 
physicians. County funding for buprenorphine was also noted as a facilitator by Molfenter et al. 
Overall, increased funding or reimbursement towards buprenorphine-related services is clearly 
a prominent facilitator of buprenorphine adoption.  
 
Training 
Specific training in the use of buprenorphine was also a prominent facilitator in the reviewed 
articles. Gordon et al noted that established training and education was a key facilitator in 
getting buprenorphine into their VA facilities. McMurphy et al also emphasized training 
opportunities specific to the management of addicted patients. A respondent quote from the 
article illustrates the point:  “I think the training that took place for this would have to be by 
people who have done it and would have to be down and dirty basic stuff on how to do this, not 
sort of textbook academic type stuff, but real day to day…” (p.548) Other suggestions included 
continuing medical education (CME) credits, and free/reimbursed training for buprenorphine 
use.  
 
Support 
The literature also suggested that the presence of advice from providers with experience, as 
well as support services would increase the likelihood of buprenorphine use. On-call addiction 
specialist & expert support was a possible facilitator mentioned in two articles, an especially 
relevant variable for interested primary care physicians. Access to greater social services and 
mental health professionals for more comprehensive care of opioid dependent patients was 
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another facilitator. Finally, shared information was identified as a facilitator, in the form of 
information about model clinics (e.g.. clinics that had successfully implemented buprenorphine 
into their practices), as well as patient success stories. Another form of support noted by 
respondents in Hutchinson et al. was the use of follow up courses and site visits after initial 
trainings to help assist with implementation of buprenorphine. Larger scale organizational 
support of buprenorphine use was also noted as a potential facilitator. 
 
 
Other facilitators 
Demonstrated patient need.  Gordon et al found that patient need and desire for 
buprenorphine, via pressing opioid addiction rates and stated desire for buprenorphine MAT, 
was a facilitator towards buprenorphine adoption. Patient requests and availability of 
buprenorphine locally were identified as facilitators by Suzuki et al.  
Champion” staff member.  Gordon et al noted that the presence of a buprenorphine 
“champion,” or a staff member that was passionate and was an advocate for the use of 
buprenorphine, was a facilitator towards adoption, by providing motivation to overcome barriers 
and change the local clinic culture.  
Time: this facilitator is interwoven with support and financial incentives, but two articles 
noted that more time allocated for opioid dependent patients would help facilitate use of 
buprenorphine.  
Residency training was noted to be a facilitator by Suzuki et al, in that psychiatrists that 
had completed any amount of buprenorphine training during residency were found to have a 
lower likelihood of reporting barriers to prescribing buprenorphine as compared to those that 
had not completed any training.  
 
Policy Analysis  
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Beyond understanding the barriers and facilitators affecting provider buprenorphine adoption, 
identifying the relevant policies promoting or inhibiting these barriers & facilitators is a useful 
task, in order to help inform the relationship between policy and practice. Generally, 
buprenorphine use is tied to general policy decisions and moves regarding substance abuse 
treatment as a whole. Substance abuse treatment has become an increasing focus of policy 
decisions as the epidemic continues across the country. This section will examine these policy 
decisions, detail their effects on the barriers to treatment described earlier in this paper, and 
explore what policy movement might ideally address provider barriers to buprenorphine 
adoption.  
 
Current Policy 
Two intertwined policy fixtures that have large roles in the realm of substance abuse treatment 
are Medicaid and the Affordable Care Act (ACA). Medicaid is the largest single funding source 
of substance abuse treatment nationwide (Burns et al, 2016), covering (along with CHIP) 3 out 
of 10 individuals with opioid addiction (Kaiser Family Foundation, 2017). Medicaid has 
historically been a significant funding source of substance abuse treatment, but its role has 
increased substantially after the passage of the ACA, largely as a result of the ACA’s Medicaid 
expansion. Specific to MAT, in 2013 only 5 states had Medicaid policies that excluded coverage 
for methadone and buprenorphine (Burns et al, 2016); and by 2016, all states covered MAT, as 
mandated by the ACA (Vestal, 2016), and all state Medicaid agencies carried buprenorphine on 
their formulary.  Medicaid funding of buprenorphine treatment is a very important variable in the 
explanation of physician adoption:  a report found that public sector reimbursement of office-
based buprenorphine treatment is associated with more waivered physicians in a given state 
(Stein et al, 2015). 
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The ACA has been an important pillar for substance abuse treatment for reasons beyond 
Medicaid expansion. The ACA has affected substance abuse treatment through four main 
areas: insurance coverage expansion; insurance reforms mandating inclusion of substance 
abuse treatment; mandating parity of treatment funding; and treatment and delivery reforms 
(Abraham et al, 2016).  One mandate of the legislation states that substance abuse treatment 
be included as an essential health benefit in private health plans and in Medicaid (Clemans-
Cope, 2017). In private health plans, such as those in the marketplaces, there must be 
coverage of at least one drug from the category of buprenorphine, 
buprenorphine/naloxone(suboxone), and naltrexone (Clemans-Cope et al., 2017). Additionally, 
The ACA has resulted in the expansion of Medicaid to all individuals up to 138% FPL in 31 
states and the District of Columbia, which has conferred substance abuse treatment to millions 
of previously ineligible individuals. The ACA also mandates that all plans in the private health 
insurance marketplace can’t have provisions for substance abuse services that have limits less 
favorable than those imposed on medical and surgical benefits, clarifying prior legislation from 
the Mental Health Parity and Addiction Equity Act. Other effects of the ACA include funding for 
delivery reform and promotion of coordinated care initiatives (Clemans-Cope et al, 2017). This 
expansion has been beneficial for many states confronting the epidemic - for example, 
Kentucky, a state with high rates of opioid addiction, experienced an increase in the number of 
waivered physicians following Medicaid expansion, and 13,000 Kentucky residents were able to 
receive substance abuse treatment in 2014 (Wright and Vanderford). Another example is found 
in New Hampshire, where the state was able to connect 10,000 people to substance abuse 
treatment in 2015 after Medicaid expansion (Rodriguez, 2016).  
 
Aside from Medicaid expansion, some states have taken on larger roles in confronting the 
opioid epidemic. Vermont, a state that has been affected by the epidemic, has taken 
considerable steps to reorganize the health system and expand access to treatment. For 
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example, the state has set up regional hubs of opioid assessment and treatments, as well as 
put into place efforts to shift treatment from residential-based treatment towards primary care 
doctors, counselors and therapists in order to increase access to treatment (Kardish, 2015) 
 
Increased funding via the ACA and Medicaid has led to greater access to treatment, and helps 
to reduce barriers related to financing. This has occurred by helping to lower costs to the 
patient, as well as providing incentive for providers to adopt buprenorphine, such that providers 
would not be offering potentially uncompensated care to patients. However, some challenges to 
Medicaid coverage of substance abuse treatment and buprenorphine use remain. Generally, 
there is considerable variation in state Medicaid policies regarding reimbursement and limits to 
coverage of MAT (Rinaldo & Rinaldo, 2013). Buprenorphine is carried on the formulary of every 
state Medicaid agency, but it is frequently subject to “specific and complex” limitations in many 
states (Rinaldo & Rinaldo, 2013). A 2016 report found that all Medicaid programs save one had 
limits imposed on buprenorphine use - examples of these limits included prior authorization, 
documentation of counseling with a buprenorphine prescription, lifetime limits, and maximum 
daily limits (Grogan et al, 2016) . Another example is the requirement of “step therapy,” which 
mandates documentation of trying another therapy first before “resorting” to buprenorphine 
(Clemans-Cope et al, 2016). 
 
These limitations are driven by many factors, including concerns over costs and fear of 
diversion, despite evidence demonstrating that restricting access to buprenorphine does not 
lower expenditures for Medicaid or reduce mortality (Clark et al, 2011). Another example of 
limitations fueled by fears over diversion can be found in Tennessee, where the “Addiction and 
Treatment Act of 2015” was passed in response to high prescribing rates and concerns about 
buprenorphine abuse, and put into place daily limits before one must be referred to an addiction 
specialist, as well as restrictions on the prescribing of buprenorphine mono-product (subutex) 
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(McGivern, 2015). Finally, largely for political reasons (Goodnough, 2015), many states chose 
not to expand Medicaid to 138% FPL. Lack of expansion excludes individuals in those states 
from addiction coverage, as well as excluding providers in those states from receiving a funding 
source for potentially treating patients with opioid abuse disorder. One way of quantifying the 
result of this variation in state Medicaid policy is examining overall Medicaid funding of total 
buprenorphine prescriptions in a state.  Vestal(2016) . found considerable state by state 
variation, with Vermont having more than 60% of prescriptions paid by Medicaid, and 
Mississippi having less than 10% on the low end (Vestal, 2016). This variation is partially 
explained by Vermont being an expansion state, while Mississippi did not expand Medicaid.  
 
Another piece of relevant legislation is the aforementioned Comprehensive Addiction and 
Recovery Act, or CARA, signed in 2016. Its provisions included increased funding of grants to 
expand the availability of MAT, expansion of prescribing privileges to NPs and PAs under the 
SAMHSA waiver program, as well as implementation of guidelines regarding ongoing review of 
the patient limit.  Also around this time, the U.S. Department of Health and Human Services 
(HHS) increased the maximum patient limit for buprenorphine prescribing providers from 100 to 
275. Expanding prescribing benefits to midlevel providers such as PAs and NPs has some 
potential benefits. In many areas, particularly rural areas that often have a high burden of opioid 
addiction, medical services are more likely to be provided by mid-level provides, especially NPs 
(Van Vleet and Paradise, 2015). As there are over 300,000 NPs and PAs nationwide (Vestal,  
2017), expanding prescribing privileges to these providers could help increase access to 
buprenorphine in areas that urgently need the help.. Even if only a fraction of these providers 
obtained the SAMHSA waiver and actually prescribed buprenorphine at rates similar to those of 
MD and DO prescribers, that would represent an improvement over the status quo. Despite this 
federal legislation, however, NPs and PAs are not actually able to prescribe buprenorphine in 
many states largely due to scope of practice disputes (Van Vleet and Paradise, 2015). 
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Specifically, many states have laws preventing NPs or PAs from prescribing buprenorphine 
unless they are working with a waivered physician, while some state laws include outright 
prohibitions on NP and PA prescribing, despite oversight (Vestal, 2017). Additionally, some of 
the larger provisions of CARA with regard to treatment have not actually been funded(Frank, 
2016). 
 
Moving Forward 
Looking into the future of substance abuse treatment and MAT, it is clear much will be 
dependent on the current contentious topic of health reform. At the time of this writing, the ACA 
and Medicaid expansion remain sources of considerable political disagreement. If Medicaid 
and/or the ACA were to be repealed, that would represent a dramatic reduction in access to 
substance abuse treatment nationwide, unless potential replacement solutions have similar or 
expanded provisions for substance abuse treatment. While that debate continues, some 
financial and reimbursement considerations could help increase uptake of buprenorphine 
among providers. For example, if Medicaid remains the primary funder of substance abuse 
treatment moving forward, increased reimbursement rates for substance abuse treatment and 
MAT, as well as removal of restrictions and limitations like pre-authorization, could help create a 
better regulatory and financial environment to facilitate adoption. Another possibility is the use of 
vouchers, such that MAT remains affordable for patients despite insurance status.  
 
It is also evident that there must be policy solutions and strategy separate from insurance & 
reimbursement regulations in order to increase access and uptake of buprenorphine. There is 
evidence supporting non-reimbursement based strategies that could be useful for increasing 
buprenorphine uptake. For example, Stein et al identified non-reimbursement strategies that 
were associated with more buprenorphine waivered physicians per capita, which included 
specific state guidance on use of buprenorphine, and the use of clinical guidelines for 
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buprenorphine use. Actions that might facilitate easier delivery of buprenorphine might also be 
useful for increasing provider uptake of buprenorphine. Other health systems across the globe 
have developed innovative solutions tothe problems of delivery of substance abuse treatment.  
For example, Canada has used telemedicine to connect patients with prescribing physicians for 
MAT. Another example is the use of pharmacy disbursement and direct observation of 
buprenorphine in order to increase access (Williams & Bisaga, 2016). Funding for physician 
support services could also go a long way toward increasing buprenorphine adoption rates. 
Examples of this include funding of expert support (such as addiction specialists) available on 
call, which was a noted facilitator in this review. This would be particularly useful for primary 
care doctors such as family medicine and general internists who are interested in caring for the 
addiction population.  
 
Changes in buprenorphine practice guidelines could also help increase provider uptake and 
increase access.  One proposal is initiating buprenorphine as soon as possible when treating a 
patient with opioid addiction, even in absence of counseling services or other support structures 
(Vestal, 2016). Experts are in agreement that buprenorphine should ideally be accompanied by 
counseling and other support methods. However, as detailed in the literature, the lack of 
counseling and support services inhibits many providers from offering buprenorphine in 
accordance to state guidelines, and thus represents a barrier to uptake. Even in the absence of 
support services, there may be considerable benefit to patients taking buprenorphine:  if more 
patients are able to access buprenorphine treatment as a result of removing requirements of 
immediate co-receipt of counseling services, the population-level benefits of more individuals on 
treatment might prove substantial, even if the benefit to the individual patient might be slightly 
less. To that end, a report demonstrated no difference in efficacy between extended counseling 
co-administered with buprenorphine as compared to limited nurse-administered counseling with 
buprenorphine in retaining patients in treatment and reducing frequency of illicit opioid use 
 21 
 
(Fiellin et al, 2006), lending credence to the potential benefit of reducing the requirement of 
mandatory co-administration of counseling from a dedicated therapist.   
 
Raising the maximum number of patients that a waivered physician can serve to help facilitate 
access. One consideration with that approach is that most waivered physicians don’t prescribe 
buprenorphine at all, and many that prescribe don’t approach their patient cap. A report found 
that that the number of waivered physicians at the 100 patient limit level was mostly associated 
with an increased amount of buprenorphine dispensed, in comparison to an overall increase of 
buprenorphine waivered physicians, and substance abuse treatment facilities using 
buprenorphine (Stein et al, 2015). Additionally, the study had findings suggesting that 
physicians waived to treat only 30 patients are likely to not treat patients with buprenorphine at 
all (Stein et al, 2015). This suggests that the physicians that are actively treating patients with 
buprenorphine are the ones pushing to increase their limit to the maximum allowed level. While 
the maximum patient cap has been expanded to 275 patients, this report suggests that a further 
relaxation in patient limit could help improve access to buprenorphine. However, the report also 
suggests that an important step will be to induce providers not just to became waivered, but to 
also become motivated to actually provide buprenorphine to patients.  
 
Legislation along with other state reforms have had varying effects on the funding opportunities 
and reimbursement strategies for substance abuse treatment and buprenorphine use, but one 
crucial barrier has gone relatively unaddressed: that of stigma. Increasing funding & 
reimbursement opportunities, as well as other strategies to facilitate buprenorphine access, 
might prove useful to connecting more patients to treatment up to a certain point, but maximum 
benefit is still dependent on primary care providers and other physicians becoming willing to 
take on these patients and provide them with treatment. As this review makes clear, provider 
unwillingness to deal with people with addiction, as well as stigmatization of addiction itself, are 
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key variables leading to a lack of provider adoption of buprenorphine. For example, despite the 
reforms that states such as Vermont are taking to combat the opioid epidemic, there has still 
been resistance from primary care providers, and the shortage of primary care physicians willing 
to take on patients with drug addiction has reduced the benefit of the regulatory changes 
(Kardish, 2015). Therefore, there should ideally be policy and legislation that directly addresses 
this stigma, or provides powerful enough incentives to override the stigma and reluctance to 
care for this population.  
 
One possible method of reducing stigma among providers is by intervening at the earlier stages 
of a clinician’s career, e.g. during medical school and residency, via the use of training and 
exposure to people with addiction and substance abuse treatment. It is well documented that 
there is little training in substance abuse and addiction during medical school, let alone opioid-
specific abuse and treatment modalities (Vestal, 2016). Lack of early exposure and training can 
lead to misunderstanding, ignorance, and negative attitudes about addiction treatment; siloing 
responsibility in the area of dedicated addiction treatment alone, rather than creating an 
environment of shared responsibility for the addiction population among all providers. Increased 
training programs and exposure early in a physician's career could prove essential to changing 
this dynamic. It could also help reduce the belief of many providers that abstinence-only 
treatment should be the sole method of substance abuse treatment, another barrier identified in 
this review. A report describing the dispositions of a panel of psychiatrists noted that completion 
of any training during residency was associated with a more favorable view of the use of 
buprenorphine (Suzuki et al, 2014). Kininis et al (2013) detailed an example of a buprenorphine 
training program (BupEd), oriented towards primary care residents, that was shown to be 
feasible and effective in exposing residents to buprenorphine and providing education about the 
medication. It serves as a model that could be replicated in other medical schools and residency 
programs. Of course, there is still a need to train and raise awareness amongst physicians that 
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have completed graduate medical training – this goal could be achieved via mandatory or highly 
encouraged (e.g. accompanied by financial benefits) continuing medical education (CME) which 
detail the use and benefits of buprenorphine and MAT in general. 
 
Increased funding of addiction services, to be added on top of normal Medicaid & private 
insurance rates, could serve as a facilitator that counteracts the disincentive that providers’ 
stigmatized views might create. Increased funding might also help with other identified barriers 
such as lack of time and lack of resources, as increased money brought in from seeing these 
patients in clinic could help fund some of these services. Increased funding to the provider/clinic 
could also incentivize providers to spend more time with these patients, as well as give clinics 
greater flexibility and ability to finance associated social services and staff training. Increasing 
reimbursement and making it financially advantageous could help reduce the barrier of stigma 
and increase provider uptake, although regulatory oversight would have to be effective as to 
discourage the buprenorphine equivalent of opioid “pill mills.” Where could this funding come 
from? One potential source, previously mentioned in this article, is in the form of increased 
remuneration via Medicaid & private insurance for buprenorphine treatment and wraparound 
services related to addiction treatment. Another potential source could be grants via state and 
federal legislation – for example like the grants found in the aforementioned CARA. Section 301 
of CARA calls for the authorization of $25 million yearly towards providing grants to substance 
abuse agencies, local governments, and non-profits located in areas with high rates and/or 
rapid increases in opioid abuse (ASAM, 2017). However, as previously mentioned, funds have 
not been appropriated to this act despite its passage into law, thus these grants remain 
unfunded (Frank, 2016).  Realizing the importance of addiction treatment in general, and the 
potential of buprenorphine therapy specifically, should be a priority for government agencies 
and other funding entities.  
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Comparing the opioid epidemic to the the HIV/AIDS epidemic provides a measure of hope that 
attitudes might change moving forward, as well as providing a model to emulate in turning it 
from a marginalized, stigmatized disease into a condition that the medical community takes 
ownership of (Vestal et al, 2016; Williams & Bisaga, 2016; Williams et al, 2017). HIV/AIDS was 
initially viewed almost entirely as a disease of moral/character failure, and potential treatment & 
prevention solutions were marginalized. As the epidemic continued to worsen, the paradigm 
began to shift. Increased funding and attention to the development of evidence based 
treatments led to the development and wide scale adoption of highly active antiretroviral therapy 
(HAART). Funding sources such as the Ryan White HIV/AIDS program allowed for the financing 
of medical treatments as well as associated wrap-around care such as social workers and care 
managers. Clinicians also began to receive increased training about HIV/AIDS, which changed 
provider understanding and attitudes about the disease. While there are still considerable gaps 
in treatment and access, HIV/AIDS is now viewed largely as serious chronic disease rather than 
a fatal result of moral failure. The epidemic has been slowed considerably by the widespread 
adoption of accepted treatment methods, proliferation of funding sources, and changes in 
beliefs and attitudes within the provider community. This same potential exists to bend the curve 
of  the opioid epidemic. Few clinicians today would advocate that a medically indicated patient 
stop taking HAART because it is morally “weak” to accept help from medication. Likewise, few 
clinicians today are concerned by the idea that HIV/AIDS patients might remain on HAART for 
the rest of their lives. Yet providers still hold these attitudes about the correlates in the opioid 
epidemic:  fear of indefinite opioid maintenance therapy and belief in abstinence based therapy 
as morally superior choices to MAT are still prevalent attitudes amongst physicians. Attitudes 
toward buprenorphine and other methods of MAT need to shift, as attitudes to HIV/AIDS did. 
The possibility that a patient remains on maintenance therapy for the rest of his or her life 
should be seen as an acceptable outcome, not a bug in the system - similar to how diabetic 
patients remaining on insulin therapy for the rest of their lives is seen as acceptable by the 
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medical community. This increased training could also raise the number of buprenorphine 
“champions” in practice, which was identified as a facilitator to buprenorphine adoption in this 
review. 
 
Of course, training & exposure need not be limited to medical school and residency. Possibilities 
such as free/paid training and mandatory CME about opioid abuse & treatment for certain 
specialties are all ideas that might help improve awareness and education, and reduce stigma. 
Other variables that appeared to mitigate stigma included awareness of “success stories” - 
patients that had experienced dramatic life improvements after starting buprenorphine - and 
connections with “model clinics” that had successfully implemented buprenorphine into their 
practices. Wide disbursement of information about model clinics and patient success stories 
could also prove useful in reducing provider stigma and increasing uptake.  
 
All the measures described above will likely require investment of money, and/or its more 
efficient use, to initiate, which may prove challenging in the current political climate. However, a 
compelling case could be made for the necessity of increased funding. Compared to the total 
costs of the continued epidemic, which are estimated to be on the scale of billions, measures to 
improve buprenorphine uptake and access would produce expenditures in the short term but 
would likely have long-term financial savings. The savings would come from reduced criminal 
justice and health care costs, as well as restored productivity that may have been otherwise lost 
due to hospitalization, incarceration, addiction, and premature death. As this epidemic worsens, 
addressing it through multiple methods, including treatment, will be an increasingly important 
goal of policymakers and stakeholders. Moves that would increase training opportunities, 
implement easily accessible support services, and increase remuneration for buprenorphine 
related services would go a long way towards addressing barriers to buprenorphine adoption.  
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Summary, Limitations & Conclusion 
This paper sought to examine buprenorphine use for opioid abuse treatment by conducting  a 
limited systematic review of the literature and an inquiry into relevant policy. The limited 
systematic review included 9 articles, 3 of which were interview-based and 6 of which were 
survey/questionnaire based. Prominent barriers depicted in the literature are stigma, lack of 
support services, lack of time, and lack of training. Other identified themes included fears about 
diversion, disagreement with the philosophy of MAT, disagreement over primary care 
responsibility for opioid abuse treatment, regulations, and cost to the patient and clinic in 
providing buprenorphine. Facilitators to buprenorphine use among providers were increased 
funding, support, and time.  
 
Two of the major themes identified in an earlier review mostly limited to methadone treatment 
were that providers believed that opioid dependent patients were more complex than other 
patients in their practice, and that many physicians felt the need for additional support services. 
Other barriers identified in their review were fear of disruption of the practice, uncertainty of 
competence to provide care, as well as disagreement with treatment philosophy. Many of these 
identified themes were present in this review as well, suggesting that buprenorphine may suffer 
from the same challenges that affected methadone use, and that these issues have not faded 
with time.  
 
The ACA and Medicaid have both produced advances in coverage and access, but these 
advances are threatened by health reform debates at the time of this writing. Coverage aside, 
more widespread adoption of buprenorphine for treatment of patients with opioid addiction will 
require a change in the culture and beliefs of the provider community at large. This culture 
change would hopefully promote the belief that opioid addiction is a medical issue, help dispel 
stigmatizing beliefs and attitudes, and spur more providers to play a role in substance abuse 
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treatment. Future policy solutions should keep this culture change as a goal, while providing for 
support services to help assist providers that have already chosen to treat patients with 
buprenorphine.  
 
Data Limitations 
The evidence undergirding this assessment of buprenorphine use includes data limitations.  
Research designs relying on interviews can be subject to poor external generalizability, due to 
low sample size as well as limited interview penetration & confinement to a particular 
geographic area or health system type. There may also be differences between those who 
choose to take part in the interview process and those who do not. Studies such as these are 
generally useful for shedding light on themes and concepts but not good at discerning firm 
conclusions. While themes were consistent throughout reviewed articles, implying that there 
may be some generalizability; it is hard to know conclusively if the barriers and themes identified 
in this review represent those held by all potential prescribers of buprenorphine across the 
nation. Larger national samples of provider respondents would help assess the robustness of 
the conclusions in this review. 
 
Study limitations 
This study has some limitations as well. This review was performed by one author, without 
multiple assessors, meaning that articles to be included or themes identified were not obtained 
via independent coding, consensus opinion, or determined after discussion, but rather subject to 
the determination of one person. Additionally, this review did not systematically attempt to 
identify unpublished literature. Finally, this paper reviewed articles that detailed the opinions of 
primary care doctors that prescribe buprenorphine as well as psychiatrists/addiction specialists, 
which may represent a conflation of findings. However, findings from the review suggest that 
providers from these different fields encountered some common barriers to buprenorphine MAT 
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use, indicating that combining studies involving different fields of medicine was a useful 
exercise.  
 
Conclusion 
This research suggests that many barriers to more widespread adoption of buprenorphine for 
MAT remain. Stigma, lack of education, and lack of support were prominent barriers identified 
by this study. Some facilitators of buprenorphine adoption were also discussed in the reviewed 
studies, and included increased remuneration, educational opportunities, presence of a 
“champion” of buprenorphine MAT, and greater access to support services. As the burden of 
opioid addiction and abuse continues to grow in our country, access to MAT will only become 
more and more important, and buprenorphine remains the most feasible tool in the arsenal to 
expand treatment on a wide scale. Steps that incentivize providers to overcome discomfort with 
opioid-dependent patient populations and provide increased levels of training and support 
services should be considered in order to help combat this ongoing epidemic. 
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Appendix:  
  
 
Figure 1: Flow Diagram of Article Inclusion  
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Table: Articles Included for Review 
Author Sample Data 
Collection 
Findings with regard to barriers 
Cunningham et al, 
2006 
99 resident and attending 
physicians from universital 
hospital associated clinics 
in Bronx, NY 
Adapted 
questionnaire 
Most common barriers: 1. Lack of knowledge or 
training, 2. Lack of time, 3. Belief that opioid 
treatment is not a primary care issue, 4. Lack of 
available supportive structures or services. 
DeFlavio et al, 2015 108 family physicians in 
Vermont and New 
Hampshire 
Anonymous 
online survey 
Most common barriers: 1. Inadequately trained 
staff, 2. Insufficient time, 3. Inadequate office 
space, 4. Regulations 
  
Themes from open ended questions: lack of 
knowledge, mistrust and difficulty with patient 
population, lack of time and interest 
Gordon et al 61 interviews with key 
personnel at 17 Veterans 
Health Affairs facilities 
Semi-structured 
interviews 
Most common patient-based barriers: lack of 
perceived need 
Most common provider barriers: lack of 
education/training, resistance to change, stigma 
towards population, abstinence based philosophy 
Hutchinson et al, 2014 92 physicians trained via 
Rural Opioid Addiction 
Management Project in 
Washington State 
Questionnaire Most frequently reported barrier: lack of mental 
health and psychosocial support, time constraints, 
lack of specialty backup, lack of confidence in 
ability to manage opioid addiction, resistance from 
practice partners, lack of institutional support 
  
Significant association between prescribing 
buprenorphine and having a partner who was 
waivered to prescribe buprenorphine 
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Kissin et al, 2006 545 nationwide addiction 
specialists that had 
completed waiver 
Questionnaire Challenges amongst waivered physicians: not 
viewing treatment as effective, not knowing 
effectiveness of drug. 
Challenges to prescribing: 30 patient limit, fear of 
DEA involvement, limited buprenorphine 
availability, lack of patient compliance. 
Open answered responses about barriers: stigma 
associated with treating patients, lack of familiarity, 
uncertainty about effectiveness. 
McMurphy et al, 2006 27 NY state primary care 
clinic directors 
Qualitative 
interviews 
Less than half of respondents knew about 
buprenorphine, all aware of methadone 
  
Most common barriers: stigma about patient 
population, fears about mixing populations in clinic, 
fear of stigma at clinic, lack of training, finances 
Molfenter et al, 2015 18 county boards and 36 
addiction treatment 
providers 
Interviews Shared barriers between providers and payors 
Most common barriers: negative attitudes towards 
use of buprenorphine, physicians unwillingness to 
work with addiction population, payment 
environment, patient caps 
Suzuki et al , 2014 93 nationwide psychiatrists 
that had completed 
buprenorphine training 
during residency 
Online survey Commonly identified barriers: lack of training, no 
supervision from mentors, do not want to attract 
patients with opioid addiction to office, lack of 
counseling, logistics, lack of institutional support 
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Thomas et al, 2008 495 total addiction 
specialists and non-
addiction specialist 
psychiatrists 
Survey Prescribing at time of study limited to addiction 
specialists, not yet proliferated greatly to general 
psychiatrists 
Most common barriers among non-prescribers: 
does not fit with practices, does not have samples, 
would change patient mix undesirably 
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CASP Quality Assessment for Qualitative Studies  
Number Question 
1.    Was there a clear statement of the aims of the research? 
2.    Is the qualitative methodology appropriate? 
3.    Was the research design appropriate to address the aims of the research? 
4.    Was the recruitment strategy appropriate to the aims of the research? 
5.    Was the data collected in a way that addressed the research issue? 
6.    Has the relationship between researcher and participants been adequately 
considered? 
7.    Have ethical issues been taken into consideration? 
8.    Was the data analysis sufficiently rigorous? 
9.    Is there a clear statement of findings? 
  
  
  
 34 
 
Adapted Tool for Quality Assessment: 
Combined from: https://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-
reduction/tools/cohort and http://journals.sagepub.com/doi/full/10.1177/1557988315626508 and 
CAPS 
Questions 
1.    Was the research question or objective in this paper clearly stated? 
2.    Was the study population clearly specified and defined? 
3.    Was the recruitment strategy appropriate to the aims of the research? 
4.    Was the participation rate of eligible persons at least 50%? 
5.    Was the instrument used reliable? 
6.    Was the instrument used valid? 
7.    Has the relationship between researcher and participants been adequately 
considered? 
8.    Was it a primary data source? 
9.    Is there a clear statement of findings? 
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Quality Assessment of Articles 
Qualitative study review (CAPS) 
  Was 
there a 
clear 
statement 
of the 
aims of 
the 
research? 
  
Is the 
qualitative 
methodology 
appropriate? 
Was the 
research 
design 
appropriate 
to address 
the aims of 
the 
research? 
Was the 
recruitment 
strategy 
appropriate 
to the aims 
of the 
research? 
Was the 
data 
collected 
in a way 
that 
addressed 
the 
research 
issue? 
Has the 
relationship 
between 
researcher 
and 
participants 
been 
adequately 
considered? 
Have ethical 
issues been 
taken into 
consideration
? 
Was the 
data 
analysis 
sufficiently 
rigorous? 
Is there a 
clear 
statement 
of 
findings? 
Gordon et 
al 
Yes Yes Yes Yes Yes Can’t 
tell 
Yes Yes Yes 
McMurphy 
et al 
Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Molfenter et 
al 
Yes Yes Yes Yes Yes Yes Yes Yes Yes 
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Adapted questionnaire / descriptive study quality review 
  Was the 
research 
question 
or 
objective 
in this 
paper 
clearly 
stated? 
Was the 
study 
population 
clearly 
specified 
and 
defined? 
Was the 
recruitment 
strategy 
appropriate to 
the aims of the 
research? 
Was the 
participation 
rate of eligible 
persons at 
least 50%? 
Was the 
instrument 
used 
reliable? 
Was the 
instrument 
used 
valid? 
Has the 
relationship 
between 
researcher 
and 
participants 
been 
adequately 
considered?
? 
Was it a 
primary 
data 
source? 
Is there a 
clear 
statement 
of 
findings? 
Cunningham 
et al 
Yes Yes Yes Yes No No Yes Yes Yes 
DeFlavio et 
al 
Yes Yes Yes Unclear No Yes Yes Yes Yes 
Hutchinson 
et al 
Yes Yes Yes Yes No No Yes Yes Yes 
Kissin et al Yes Yes Yes Yes No No Yes Yes Yes 
Suzuki et al Yes Yes Unclear No No No Yes Yes Yes 
Thomas et 
al 
Yes Yes Yes Yes No No Yes Yes Yes 
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